tetano
Editor, Senior Moderator
PLoS One
. 2023 Sep 14;18(9):e0291537.
doi: 10.1371/journal.pone.0291537. eCollection 2023. Animal efficacy study of a plant extract complex (BEN815) as a potential treatment for COVID-19
Moon Ho Do[SUP] 1 [/SUP], Hua Li[SUP] 1 [/SUP], Su Yeon Cho[SUP] 1 [/SUP], Subin Oh[SUP] 1 [/SUP], Ju Hwan Jeong[SUP] 2 [/SUP], Min-Suk Song[SUP] 2 [/SUP], Jong-Moon Jeong[SUP] 1 3 [/SUP]
Affiliations
In a short time, several types of injectable and oral therapeutics have been developed and used to effectively manage patients with coronavirus disease 2019 (COVID-19). BEN815 is an improved mixture of three extracts (Psidium guajava, Camellia sinensis, and Rosa hybrida) recognized by the Ministry of Food and Drug Safety of Korea as a health food ingredient that alleviates allergic rhinitis. The current animal efficacy study was performed to assess its probability of improving COVID-19 symptoms. BEN815 treatment significantly increased the survival of K18-hACE2 transgenic mice and reduced viral titers in the lungs at 5 days post infection (DPI). Furthermore, the lungs of the treated mice showed mild tissue damage at 5 DPI and nearly complete recovery from COVID-19 at 14 DPI. BEN815 appears to be an effective and minimally toxic anti-SARS-CoV-2 agent in mice and has potential for clinical applications.
. 2023 Sep 14;18(9):e0291537.
doi: 10.1371/journal.pone.0291537. eCollection 2023. Animal efficacy study of a plant extract complex (BEN815) as a potential treatment for COVID-19
Moon Ho Do[SUP] 1 [/SUP], Hua Li[SUP] 1 [/SUP], Su Yeon Cho[SUP] 1 [/SUP], Subin Oh[SUP] 1 [/SUP], Ju Hwan Jeong[SUP] 2 [/SUP], Min-Suk Song[SUP] 2 [/SUP], Jong-Moon Jeong[SUP] 1 3 [/SUP]
Affiliations
- PMID: 37708114
- DOI: 10.1371/journal.pone.0291537
In a short time, several types of injectable and oral therapeutics have been developed and used to effectively manage patients with coronavirus disease 2019 (COVID-19). BEN815 is an improved mixture of three extracts (Psidium guajava, Camellia sinensis, and Rosa hybrida) recognized by the Ministry of Food and Drug Safety of Korea as a health food ingredient that alleviates allergic rhinitis. The current animal efficacy study was performed to assess its probability of improving COVID-19 symptoms. BEN815 treatment significantly increased the survival of K18-hACE2 transgenic mice and reduced viral titers in the lungs at 5 days post infection (DPI). Furthermore, the lungs of the treated mice showed mild tissue damage at 5 DPI and nearly complete recovery from COVID-19 at 14 DPI. BEN815 appears to be an effective and minimally toxic anti-SARS-CoV-2 agent in mice and has potential for clinical applications.